3 ASX Penny Stocks With Market Caps Larger Than A$80M

Tue, Aug 12, 2025, 11:05 PM 4 min read

Australian shares are experiencing a positive trend, with the ASX 200 climbing towards new all-time highs, buoyed by recent decisions from the Reserve Bank. In such an encouraging market environment, identifying stocks that balance affordability with growth potential is key. While ‘penny stocks’ might seem like a term from another era, they remain relevant for investors seeking opportunities in smaller companies with solid financial foundations and promising prospects.

Click here to see the full list of 458 stocks from our ASX Penny Stocks screener.

Here’s a peek at a few of the choices from the screener.

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Adairs Limited is a specialty retailer offering home furnishings, furniture, and decoration products in Australia and New Zealand, with a market cap of A$387.07 million.

Operations: The company’s revenue segments comprise A$423.56 million from Adairs, A$125.34 million from Focus, and A$53.57 million from Mocka.

Market Cap: A$387.07M

Adairs Limited, with a market cap of A$387.07 million, shows mixed prospects as a penny stock. While operating cash flow covers its debt well and it trades at good value compared to peers, short-term and long-term liabilities exceed its assets. The company has experienced negative earnings growth over the past year, though earnings are forecasted to grow by 12.6% annually. Despite having high-quality earnings and no significant shareholder dilution recently, Adairs faces challenges with an inexperienced management team and board. Its net debt to equity ratio is satisfactory, but dividend sustainability remains unstable due to inconsistent payouts.

• Unlock comprehensive insights into our analysis of Adairs stock in this financial health report.

• Learn about Adairs’ future growth trajectory here.

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Cogstate Limited is a neuroscience technology company that creates, validates, and commercializes digital brain health assessments for academic and industry-sponsored research, with a market cap of A$302.20 million.